230 related articles for article (PubMed ID: 38430308)
1. Cellular Alterations in Immune Checkpoint Inhibitor Therapy-Related Cardiac Dysfunction.
Michel L; Ferdinandy P; Rassaf T
Curr Heart Fail Rep; 2024 Jun; 21(3):214-223. PubMed ID: 38430308
[TBL] [Abstract][Full Text] [Related]
2. Cardiotoxicity from immune checkpoint inhibitors.
Michel L; Rassaf T; Totzeck M
Int J Cardiol Heart Vasc; 2019 Dec; 25():100420. PubMed ID: 31517036
[TBL] [Abstract][Full Text] [Related]
3. New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity.
Khunger A; Battel L; Wadhawan A; More A; Kapoor A; Agrawal N
Curr Oncol Rep; 2020 Jun; 22(7):65. PubMed ID: 32514647
[TBL] [Abstract][Full Text] [Related]
4. Cardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategies.
Sun JY; Qu Q; Lou YX; Hua Y; Sun GZ; Sun W; Kong XQ
Int J Cardiol; 2021 Dec; 344():170-178. PubMed ID: 34563597
[TBL] [Abstract][Full Text] [Related]
5. Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors.
Mladosievičová B; Országhová Z; Jablonická M; Rečková M; Chovanec M; Mego M
Klin Onkol; 2020; 33(5):350-355. PubMed ID: 33108879
[TBL] [Abstract][Full Text] [Related]
6. Cardiotoxicity of Immune Checkpoint Inhibitors.
Patel RP; Parikh R; Gunturu KS; Tariq RZ; Dani SS; Ganatra S; Nohria A
Curr Oncol Rep; 2021 May; 23(7):79. PubMed ID: 33937956
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors - the revolutionary cancer immunotherapy comes with a cardiotoxic price.
Achim A; Liblik K; Gevaert S
Trends Cardiovasc Med; 2024 Feb; 34(2):71-77. PubMed ID: 36152788
[TBL] [Abstract][Full Text] [Related]
8. Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy.
Michel L; Helfrich I; Hendgen-Cotta UB; Mincu RI; Korste S; Mrotzek SM; Spomer A; Odersky A; Rischpler C; Herrmann K; Umutlu L; Coman C; Ahrends R; Sickmann A; Löffek S; Livingstone E; Ugurel S; Zimmer L; Gunzer M; Schadendorf D; Totzeck M; Rassaf T
Eur Heart J; 2022 Jan; 43(4):316-329. PubMed ID: 34389849
[TBL] [Abstract][Full Text] [Related]
9. [Update cardio-oncology : Immune checkpoint inhibitor therapy].
Michel L; Rassaf T
Herz; 2024 Feb; 49(1):81-90. PubMed ID: 38175285
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape.
Zhu H; Ivanovic M; Nguyen A; Nguyen PK; Wu SM
J Mol Cell Cardiol; 2021 Nov; 160():121-127. PubMed ID: 34303670
[TBL] [Abstract][Full Text] [Related]
11. Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system.
Michel L; Totzeck M; Lehmann L; Finke D
Herz; 2020 Nov; 45(7):645-651. PubMed ID: 32533218
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.
Agostinetto E; Eiger D; Lambertini M; Ceppi M; Bruzzone M; Pondé N; Plummer C; Awada AH; Santoro A; Piccart-Gebhart M; de Azambuja E
Eur J Cancer; 2021 May; 148():76-91. PubMed ID: 33740500
[TBL] [Abstract][Full Text] [Related]
13. How can we manage the cardiac toxicity of immune checkpoint inhibitors?
Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G
Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484
[No Abstract] [Full Text] [Related]
14. Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors.
Pirozzi F; Poto R; Aran L; Cuomo A; Galdiero MR; Spadaro G; Abete P; Bonaduce D; Marone G; Tocchetti CG; Varricchi G; Mercurio V
Curr Oncol Rep; 2021 Jan; 23(2):13. PubMed ID: 33415405
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure.
Waliany S; Lee D; Witteles RM; Neal JW; Nguyen P; Davis MM; Salem JE; Wu SM; Moslehi JJ; Zhu H
Annu Rev Pharmacol Toxicol; 2021 Jan; 61():113-134. PubMed ID: 32776859
[TBL] [Abstract][Full Text] [Related]
16. Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity.
Guo X; Wang H; Zhou J; Li Y; Duan L; Si X; Zhang L; Fang L; Zhang L
Thorac Cancer; 2020 Feb; 11(2):475-480. PubMed ID: 31849171
[TBL] [Abstract][Full Text] [Related]
17. Cancer Therapeutics-related Cardiac Dysfunction in Patients Treated With Immune Checkpoint Inhibitors: An Understudied Manifestation.
Peleg Hasson S; Arnold J; Merdler I; Sivan A; Shamai S; Geva R; Merimsky O; Shachar E; Waissengrin B; Moshkovits Y; Arbel Y; Topilsky Y; Rozenbaum Z; Wolf I; Laufer-Perl M
J Immunother; 2021 Jun; 44(5):179-184. PubMed ID: 33950028
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure.
Gergely TG; Drobni ZD; Kallikourdis M; Zhu H; Meijers WC; Neilan TG; Rassaf T; Ferdinandy P; Varga ZV
Nat Rev Cardiol; 2024 Jul; 21(7):443-462. PubMed ID: 38279046
[TBL] [Abstract][Full Text] [Related]
19. Characterization of immune checkpoint inhibitor-induced cardiotoxicity reveals interleukin-17A as a driver of cardiac dysfunction after anti-PD-1 treatment.
Gergely TG; Kucsera D; Tóth VE; Kovács T; Sayour NV; Drobni ZD; Ruppert M; Petrovich B; Ágg B; Onódi Z; Fekete N; Pállinger É; Buzás EI; Yousif LI; Meijers WC; Radovits T; Merkely B; Ferdinandy P; Varga ZV
Br J Pharmacol; 2023 Mar; 180(6):740-761. PubMed ID: 36356191
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology.
Chen DY; Huang WK; Chien-Chia Wu V; Chang WC; Chen JS; Chuang CK; Chu PH
J Formos Med Assoc; 2020 Oct; 119(10):1461-1475. PubMed ID: 31444018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
